BCM
DSGN icon

BML Capital Management’s Design Therapeutics DSGN Stock Holding History

BML Capital Management’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-421,749
Closed -$1.41M – 31
2024
Q2 		$1.41M Sell
421,749
-457,729
-52% -$1.78M 1.01% 17
2024
Q1 		$3.54M Sell
879,478
-150,000
-15% -$401K 2.34% 12
2023
Q4 		$2.73M Buy
+1,029,478
New +$2.36M 2.07% 13

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BML Capital Management's DSGN Position: Q3 2024 in Review

BML Capital Management sold out of Design Therapeutics (DSGN) in Q3 2024, closing a stake of 421,749 shares — an estimated $1.41M sold.

BML Capital Management first reported a position in DSGN in Q4 2023 and held it in 3 quarters. The position peaked at $3.54M in Q1 2024. 100 funds tracked by Wall St. Rank hold DSGN as of Q3 2024.

  • BML Capital Management reported no remaining Design Therapeutics position as of Q3 2024 after selling out during the quarter.
  • BML Capital Management sold 421,749 Design Therapeutics shares in Q3 2024, an estimated $1.41M.
  • BML Capital Management first reported a position in Design Therapeutics in Q4 2023 and held it in 3 quarters.
  • BML Capital Management's Design Therapeutics position peaked at $3.54M in Q1 2024.
  • 100 funds tracked by Wall St. Rank held Design Therapeutics as of Q3 2024.

Based on BML Capital Management's 13F filing for Q3 2024, filed 5 Nov 2024.